D-1248-2019 Class I Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1248-2019 was initiated by Aurobindo Pharma USA Inc. on Mar 28, 2019 and is designated Class I. Reason for recall: Presence of Particulate Matter: One vial was found to contain a hair. The recall status is terminated (terminated Apr 11, 2024). Affected quantity: 88600 vials.

Recall details

Product Type
Drugs
Report Date
Apr 17, 2019
Initiation Date
Mar 28, 2019
Termination Date
Apr 11, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
88600 vials

Product description

Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL), 5mL vial, Rx only, Mrd. in India for: AuroMedics Pharna LLC. E Windsor, NJ 08520 NDC 55150-162-05

Reason for recall

Presence of Particulate Matter: One vial was found to contain a hair.

Distribution pattern

Product is being held at a distributor site in Mexico, Asheboro, NC, Charlotte, NC and Santa Teresa, NM and not further distributed in the U.S. Market.

Code information

Lot #: CLC180117, Exp. June 2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1248-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1248-2019. Report a data issue: hello@regdatalab.com.